World-First Nod For Yuhan's Lung Cancer Drug, In Korea
Eyes Now On J&J's Global Combo Trial
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
